Product overview
Description Anti-CAB39 rabbit polyclonal antibody
Applications ELISA, WB, IHC
Immunogen Synthetic peptide of human CAB39
Reactivity Human, Mouse
Content 0.7 mg/ml
Host species Rabbit
Ig class Immunogen-specific rabbit IgG
Purification Antigen affinity purification
Target information
Symbol CAB39
Full name calcium binding protein 39
Synonyms MO25; CGI-66
Swissprot Q9Y376
Target Background
Peutz-Jeghers Syndrome (PJS) is a rare hereditary disease characterized by melanocytic macules of the lips, gastrointestinal hamartomatous polyps and an increased risk for many classes of cancer. The serine/threonine kinase LKB1 (also designated STK11) has been identified as the gene mutated in PJS. LKB1 activity increases upon the binding of a regulatory complex consisting of the STE20-related adaptor-alpha (STRAD alpha) pseudo kinase and the calcium binding protein 39 (MO25 alpha). STRAD and MO25 determine the subcellular localization of LKB1 by initiating its translocation from the nucleus to the cytoplasm, thus regulating the tumor suppressor activity of LKB1. The LKB1/STRAD/MO25 complex acts as an AMP-activated protein kinase kinase (AMPKK).
Applications
Immunohistochemistry
Predicted cell location: Cytoplasm and Nucleus
Positive control: Human brain
Recommended dilution: 50-200 Predicted cell location: Cytoplasm and Nucleus
Positive control: Human liver cancer
Recommended dilution: 50-200
The image on the left is immunohistochemistry of paraffin-embedded Human brain tissue using ml261917(CAB39 Antibody) at dilution 1/40, on the right is treated with synthetic peptide. (Original magnification: ×200) The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using ml261917(CAB39 Antibody) at dilution 1/40, on the right is treated with synthetic peptide. (Original magnification: ×200)
Western blotting
Predicted band size:40 kDa
Positive control:Lovo cells
Recommended dilution: 500-2000